In contrast, Posilac has been banned from use in Canada, Australia, New Zealand, Japan, Israel and all European Union countries (currently numbering 27), from 2000 or earlier. In 1994 a European Union scientific commission European Union scientific commission stated that the use of rBST substantially increased health problems with cows, including foot problems, mastitis and injection site reactions, impinged on the welfare of the animals and caused reproductive disorders. The report concluded that, on the basis of the health and welfare of the animals, rBST should not be used.
In 1993, FDA approved commercial use of synthetic recombinant Bovine somatotropin or growth hormone ( rbST or rbGH) in injection form to be used in cows to increase milk yield. It was marketed under name Posilac (company Monsanto). It has shown to increase milk yield in cows by 10-15 %. On other hand there are some reports showing that use of recombinant somatotropin/growth hormones increases the incidence of mastitis, lameness and some reproductive issues in the cows. Increased mastitis can be linked to high use of antibiotics for treatment and secretion of antibiotic residue in milk and meat products. In 1990, FDA evaluated pharmaceutical company studies and concluded that the use of recombinant bovine growth hormone (rbGH) in dairy cattle presents no increased health risk to consumers and nutritional quality of milk and meat from rBST-treated cows is equivalent to that of milk and meat from untreated cows.
Friday, March 22, 2013 7:51:21 AM
Mr. Peabody: Don't know about where you live, but hormones aren`t allowed in livestock here in the Great White North. Today`s cattle have been selectively bred for milk production, and make much more than a calf needs. Sick cattle can`t be sold for slaughter in either country.